TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board

Basel, May 08, 2024 – TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB). Dr. Sandler, a leading expert in oncology research and pharmaceutical development, and former was most recently Chief Medical Officer at Mirati Therapeutics, which was acquired by Bristol Myers Squibb in 2024. (now BMS), He joins the SAB as an important addition to TOLREMO’s internal resources to support the development of an innovative approach to preventing transcriptional cancer drug resistance. The company’s lead candidate, TT125-802, is a small molecule CBP/p300 bromodomain inhibitor currently advancing through a Phase 1 clinical trial.

“Alan brings extensive experience in drug development, including clinical development experience with one of the leading KRAS inhibitors,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO. “We welcome his insights as we make important progress toward delivering a novel therapeutic solution to addressing resistance to targeted cancer therapies.”

“I have been impressed with TOLREMO’s work. The team has discovered an exciting pivotal mechanism that governs critical transcriptional resistance pathways,” said Alan Sandler, M.D., Scientific Advisory Board member at TOLREMO. “Over the course of my career, I have seen the need for an innovative approach to this form of drug resistance, and I look forward to supporting the efforts to develop TT125-802 as a backbone for resistance-preventing combination therapies.”

Dr. Alan Sandler is a distinguished leader in oncology and drug development with extensive experience in both industry and academia. His expertise spans clinical development and operations, regulatory affairs, drug safety and development strategies. Dr. Sandler previously held the position of Executive Vice President, Chief Medical Officer at Mirati Therapeutics, a Bristol Myers Squibb company. Before joining Mirati, he was the President, Global Head of Development in Oncology at Zai Lab. Prior to that, Dr. Sandler held roles of progressive responsibility at Genentech, a member of the Roche Group, where he ultimately served as Senior Vice President and Global Head, Product Development of Oncology Solid Tumors. His academic positions include roles at Oregon Health and Science University, where he served as Professor of Medicine and Head of the Division of Hematology/Medical Oncologyand Medical Lead of the Thoracic Oncology Program, and at; Vanderbilt University as an Associate Professor of Medicine and Indiana University as Assistant Professor of Medicine.. Dr. Sandler earned his M.D. from Rush Medical College and completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center. An active contributor to the medical field, he has authored over 300 publications, including peer-reviewed articles, reviews, abstracts, and book chapters.

TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors

Basel, March 21, 2024 – TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors. Both bring extensive careers in the strategic, financial and corporate development aspects of building leading biotechnology companies. Together, they will contribute to TOLREMO’s further growth and operational execution as the company advances its lead candidate, TT125-802, designed to prevent transcriptional cancer drug resistance, through a Phase 1 first-in-human clinical trial.

"We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO. “Jeff's extensive leadership experience and Mike's expertise in financial strategy within the life sciences sector are valuable assets as we continue our mission to overcome transcriptional drug resistance to a broad spectrum of targeted cancer treatments.”

"Joining TOLREMO's board is an opportunity to contribute to a company making significant strides toward surmounting a universal problem for current and future targeted cancer therapies. I am eager to support TOLREMO in its clinical stage as it advances TT125-802 and help shape the company’s corporate strategy to ensure the team’s scientific knowledge is translated into tangible benefits for patients," said Jeff Jonkers, new board member at TOLREMO.

“As a new member of the TOLREMO board, I look forward to applying my experience in guiding companies through critical growth phases to contribute to the company’s strategic financial perspective as we aim to maximize the potential of TT125-802,” said Mike Sherman, new board member at TOLREMO.

Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry. He has served as the President and CEO as well as a Director of Belharra Therapeutics since 2021, and he is currently a member of the Board of Directors of California Life Sciences. Prior to this, Jeff served as the CEO of Ambys Medicines, President of NGM Pharmaceuticals, and Senior Vice President, Corporate and Business Development at Theravance Biopharma. His other executive roles include CBO of Satori Pharmaceuticals, Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene, as well as multiple leadership positions in the business development and legal groups at Genentech. Jeff began his career at Wilson Sonsini, representing clients in the life science and high-tech industries. Jeff holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews, and a B.A. from Claremont McKenna College.

Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership. He currently serves as Board Chair at Chimerix, Inc. and as a Board Director at Werewolf Therapeutics. Prior to this, Mike was the CEO of Chimerix, where he led the company's shift from antivirals to oncology, including the FDA approval and sale of TEMBEXA® and the progression of a Phase 3 glioma trial for its lead oncology drug. Before Chimerix, he was the CEO of Endocyte, transforming its market capitalization from $200 million to a $2.1 billion acquisition by Novartis in 2018. This transformation involved pipeline re-prioritization, the acquisition of PLUVICTO®, and the execution of a Phase 3 regulatory and clinical strategy. Mike’s tenure at Endocyte originally began in 2006 as CFO, where he contributed to its IPO and various financings. His earlier career included executive roles at Guidant Corporation, a cardiovascular device manufacturer later acquired by Boston Scientific Corporation. Mike’s previous board experiences include positions at BioSpecifics Technologies, Inc., Mead Johnson Nutrition, and service as the former Chairman of the Board of Trustees for the Children’s Museum of Indianapolis. Mike holds a B.A. in Economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, where he graduated as a Tuck Scholar.

TOLREMO Treats First Patient in Phase I Trial with TT125-802, a Novel Therapeutic Agent to Overcome Transcriptional Cancer Drug Resistance

Basel, November 28, 2023 – TOLREMO therapeutics AG (TOLREMO) today announced that the first patient has been dosed in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics of its lead candidate, TT125-802, in patients across a range of solid tumor indications. TT125-802 is an orally available small molecule CBP/p300 bromodomain inhibitor designed to prevent non-genetic cancer drug resistance and thereby improve the response rates and durability of targeted cancer treatments. In preclinical testing, the compound has demonstrated the ability to block critical transcriptional resistance pathways responsible for cancer’s earliest escape mechanisms to targeted therapies.

"Initiating our Phase 1 clinical trial is an important corporate milestone for TOLREMO. With TT125-802, we are leveraging our scientific insights to develop an effective CBP/p300 inhibitor with the potential to prevent resistance mechanisms across a broad spectrum of current and future targeted cancer treatments,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO. “We are deeply committed to overcoming transcriptionally mediated cancer drug resistance for patient benefit, and this trial marks the start of an exciting new phase for the company.”

The Phase I dose-escalation study will enroll patients across a range of solid tumor indications. The primary objective will be a safety assessment of TT125-802 as a monotherapy. Secondary objectives include the analysis of the drug’s biological activity, pharmacokinetics, pharmacodynamics, and target engagement, as well as the identification of the recommended dosing regimen and potential biomarkers for future patient stratification. The trial will be conducted initially at clinical centers in Europe, with the potential to include sites in the U.S. through an open Investigational New Drug (IND) application with the Food and Drug Administration (FDA). Stepwise, TOLREMO will advance TT125-802 into clinical testing in combination with targeted therapies, such as KRAS, EGFR or AR inhibitors, in specific advanced solid tumor indications.

“TOLREMO’s in-depth preclinical analyses have showcased potency, selectivity, and safety data that demonstrate that TT125-802 has a highly differentiated profile, providing the foundation for translating these findings into the clinical setting. By specifically inhibiting transcriptional resistance pathways to targeted treatments, TT125-802 has the potential to profoundly improve the response rate and durability of other therapeutic interventions,” said Alessandra Cesano, MD, PhD, consulting Chief Medical Officer at TOLREMO therapeutics.